EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Should we be afraid of radiotherapy for hemorrhagic brain metastases? A narrative review

Aleksandra Łupicka, Weronika Kowalczyk, Bartosz Cyman, Mateusz Spałek iD

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241289203 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 15.10.2024. Verfasst von Aleksandra Łupicka und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warsaw, Poland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Maria Sklodowska-Curie National Research Institute of Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain metastases (BM) are the most common intracranial malignancies. They are responsible for death as well as impairment of quality of life and cognitive function. In some cases, BMs can cause intracranial hemorrhage, which is not only responsible for the acute onset of either a new focal neurological deficit or worsening of a preexisting focal deficit but also poses a new challenge in treatment planning and clinical management. The aim of this study was to evaluate the available treatment modalities and their efficacy in hemorrhagic brain metastases (HBMs) with special attention to radiotherapy. In this review, we searched PubMed, BMJ, NCBI, Springer, BMC Cancer, Cochrane, and Google Scholar for articles containing data on the diagnosis and treatment of patients with HBMs, excluding the pediatric population. Treatment strategies consist of neurosurgery, whole brain radiotherapy, and stereotactic techniques (fractionated stereotactic radiosurgery (fSRS)/stereotactic radiosurgery (SRS)). Although the optimal treatment strategy for HBMs has not been established, we found no convincing evidence that radiotherapy, especially fSRS/SRS, is contraindicated in HBMs. We concluded that fSRS/SRS is a promising option for patients with HBM, particularly when surgical intervention poses risks.

Schlagwörter

Stichwörter der Autor:innen

Gamma Knifebrain metastasesfractionated radiotherapyhemorrhagic brain metastasesradiotherapystereotactic radiosurgery

Autor:innen und Institutionen

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warsaw, Poland.
  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Wilhelma Konrada Roentgena 5, Warsaw 02-781, Poland.

ORCID-Profile: Mateusz Spałek

Förderung

  • Maria Sklodowska-Curie National Research Institute of Oncology

Zitieren

APA

Łupicka, A., Kowalczyk, W., Cyman, B., & Spałek, M. (2024). Should we be afraid of radiotherapy for hemorrhagic brain metastases? A narrative review. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241289203

Vancouver

Łupicka A, Kowalczyk W, Cyman B, Spałek M. Should we be afraid of radiotherapy for hemorrhagic brain metastases? A narrative review. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241289203

BibTeX
@article{upicka2024,
  author = {Łupicka, Aleksandra and Kowalczyk, Weronika and Cyman, Bartosz and Spałek, Mateusz},
  title = {Should we be afraid of radiotherapy for hemorrhagic brain metastases? A narrative review},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241289203}
}
Kostenlos starten →